| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 158 | 2024 | 5097 | 9.480 |
Why?
|
| HIV-1 | 91 | 2022 | 1260 | 8.510 |
Why?
|
| Molecular Diagnostic Techniques | 29 | 2024 | 132 | 6.730 |
Why?
|
| Viral Load | 55 | 2023 | 819 | 5.900 |
Why?
|
| Tuberculosis | 24 | 2024 | 543 | 5.190 |
Why?
|
| Drug Resistance, Viral | 38 | 2020 | 278 | 4.660 |
Why?
|
| Mycobacterium tuberculosis | 27 | 2024 | 329 | 4.600 |
Why?
|
| Humans | 255 | 2024 | 14537 | 4.270 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 20 | 2024 | 226 | 4.050 |
Why?
|
| RNA, Viral | 41 | 2022 | 303 | 3.960 |
Why?
|
| Sensitivity and Specificity | 59 | 2024 | 385 | 3.940 |
Why?
|
| Anti-HIV Agents | 49 | 2023 | 1324 | 3.560 |
Why?
|
| Tuberculosis, Pulmonary | 19 | 2024 | 324 | 3.290 |
Why?
|
| CD4 Lymphocyte Count | 30 | 2022 | 656 | 3.110 |
Why?
|
| South Africa | 106 | 2024 | 7596 | 2.960 |
Why?
|
| Anti-Retroviral Agents | 23 | 2018 | 551 | 2.870 |
Why?
|
| Point-of-Care Testing | 9 | 2022 | 71 | 2.870 |
Why?
|
| Adult | 113 | 2024 | 5913 | 2.500 |
Why?
|
| Male | 112 | 2024 | 6754 | 2.430 |
Why?
|
| Female | 123 | 2024 | 9103 | 2.190 |
Why?
|
| Middle Aged | 76 | 2024 | 3601 | 2.160 |
Why?
|
| Rifampin | 13 | 2024 | 197 | 2.140 |
Why?
|
| Microbial Sensitivity Tests | 11 | 2024 | 198 | 2.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 21 | 2016 | 472 | 2.060 |
Why?
|
| Diagnostic Tests, Routine | 8 | 2020 | 59 | 2.060 |
Why?
|
| Flow Cytometry | 17 | 2017 | 67 | 2.020 |
Why?
|
| Algorithms | 11 | 2021 | 106 | 2.000 |
Why?
|
| Point-of-Care Systems | 12 | 2020 | 91 | 1.850 |
Why?
|
| Young Adult | 43 | 2024 | 2498 | 1.830 |
Why?
|
| Reagent Kits, Diagnostic | 13 | 2021 | 56 | 1.820 |
Why?
|
| Mass Screening | 10 | 2023 | 245 | 1.740 |
Why?
|
| Drug Monitoring | 8 | 2017 | 55 | 1.690 |
Why?
|
| Scleroderma, Systemic | 10 | 2023 | 43 | 1.610 |
Why?
|
| Acquired Immunodeficiency Syndrome | 12 | 2015 | 187 | 1.480 |
Why?
|
| HIV | 14 | 2016 | 380 | 1.430 |
Why?
|
| Mutation | 17 | 2022 | 306 | 1.420 |
Why?
|
| Clinical Laboratory Techniques | 4 | 2020 | 56 | 1.370 |
Why?
|
| Blood | 9 | 2016 | 51 | 1.350 |
Why?
|
| Developing Countries | 15 | 2020 | 400 | 1.340 |
Why?
|
| Aged | 32 | 2024 | 1740 | 1.310 |
Why?
|
| Reverse Transcriptase Inhibitors | 11 | 2016 | 118 | 1.310 |
Why?
|
| Specimen Handling | 15 | 2020 | 105 | 1.260 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 15 | 2022 | 150 | 1.240 |
Why?
|
| AIDS Serodiagnosis | 5 | 2020 | 44 | 1.200 |
Why?
|
| Reproducibility of Results | 19 | 2020 | 217 | 1.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2017 | 151 | 1.190 |
Why?
|
| Adolescent | 35 | 2024 | 2985 | 1.160 |
Why?
|
| Immunophenotyping | 4 | 2017 | 24 | 1.150 |
Why?
|
| Laboratories | 7 | 2021 | 47 | 1.140 |
Why?
|
| Nucleic Acid Amplification Techniques | 5 | 2022 | 35 | 1.080 |
Why?
|
| Population Surveillance | 10 | 2021 | 325 | 1.050 |
Why?
|
| Bacteriological Techniques | 6 | 2017 | 54 | 1.020 |
Why?
|
| Coinfection | 7 | 2024 | 276 | 1.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2016 | 77 | 0.960 |
Why?
|
| Genotype | 15 | 2016 | 442 | 0.950 |
Why?
|
| Recurrence | 1 | 2024 | 29 | 0.950 |
Why?
|
| Pandemics | 4 | 2023 | 296 | 0.940 |
Why?
|
| Biological Assay | 3 | 2020 | 32 | 0.940 |
Why?
|
| Sputum | 10 | 2024 | 135 | 0.910 |
Why?
|
| Polymerase Chain Reaction | 12 | 2017 | 260 | 0.900 |
Why?
|
| Cohort Studies | 24 | 2023 | 967 | 0.850 |
Why?
|
| Infant | 26 | 2024 | 2244 | 0.850 |
Why?
|
| Immunologic Tests | 2 | 2020 | 7 | 0.820 |
Why?
|
| Drug Resistance, Bacterial | 9 | 2024 | 135 | 0.820 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2008 | 3 | 0.810 |
Why?
|
| Cost of Illness | 5 | 2020 | 167 | 0.800 |
Why?
|
| CD4 Antigens | 5 | 2016 | 49 | 0.800 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 71 | 0.800 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 104 | 0.780 |
Why?
|
| Basophils | 5 | 2011 | 5 | 0.780 |
Why?
|
| Child | 19 | 2024 | 2242 | 0.780 |
Why?
|
| Mutation, Missense | 10 | 2016 | 65 | 0.770 |
Why?
|
| Serologic Tests | 3 | 2020 | 26 | 0.760 |
Why?
|
| Drug Resistance, Multiple, Viral | 4 | 2014 | 16 | 0.750 |
Why?
|
| Quality Assurance, Health Care | 3 | 2011 | 43 | 0.730 |
Why?
|
| Betacoronavirus | 2 | 2020 | 52 | 0.730 |
Why?
|
| Primary Health Care | 4 | 2018 | 240 | 0.730 |
Why?
|
| Treatment Failure | 15 | 2016 | 175 | 0.710 |
Why?
|
| Automation, Laboratory | 2 | 2017 | 13 | 0.700 |
Why?
|
| Antibiotics, Antitubercular | 5 | 2020 | 47 | 0.690 |
Why?
|
| HIV-2 | 1 | 2020 | 15 | 0.690 |
Why?
|
| Child, Preschool | 17 | 2024 | 1748 | 0.680 |
Why?
|
| Protein Array Analysis | 2 | 2010 | 2 | 0.680 |
Why?
|
| Antiviral Agents | 5 | 2015 | 111 | 0.670 |
Why?
|
| Prospective Studies | 18 | 2024 | 1160 | 0.670 |
Why?
|
| Isoniazid | 5 | 2024 | 110 | 0.650 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 256 | 0.630 |
Why?
|
| Genotyping Techniques | 3 | 2017 | 38 | 0.630 |
Why?
|
| Blood Specimen Collection | 4 | 2013 | 13 | 0.630 |
Why?
|
| Prevalence | 14 | 2020 | 1192 | 0.620 |
Why?
|
| DNA, Viral | 12 | 2013 | 165 | 0.620 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 112 | 0.620 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2016 | 90 | 0.620 |
Why?
|
| Lymphocyte Activation | 7 | 2015 | 40 | 0.590 |
Why?
|
| HIV Antibodies | 3 | 2010 | 247 | 0.590 |
Why?
|
| Desiccation | 5 | 2016 | 15 | 0.580 |
Why?
|
| Aged, 80 and over | 10 | 2022 | 468 | 0.580 |
Why?
|
| Laboratory Proficiency Testing | 2 | 2014 | 6 | 0.580 |
Why?
|
| Directive Counseling | 1 | 2017 | 15 | 0.580 |
Why?
|
| HIV Seropositivity | 5 | 2016 | 265 | 0.570 |
Why?
|
| Feasibility Studies | 6 | 2022 | 101 | 0.570 |
Why?
|
| Students, Medical | 2 | 2015 | 14 | 0.560 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2021 | 16 | 0.560 |
Why?
|
| Antitubercular Agents | 7 | 2024 | 322 | 0.550 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 563 | 0.550 |
Why?
|
| Latent Tuberculosis | 2 | 2015 | 45 | 0.550 |
Why?
|
| Patient Compliance | 1 | 2017 | 120 | 0.540 |
Why?
|
| Disease Management | 1 | 2017 | 74 | 0.540 |
Why?
|
| Reference Standards | 4 | 2019 | 29 | 0.530 |
Why?
|
| Antibodies, Viral | 6 | 2022 | 284 | 0.530 |
Why?
|
| Guidelines as Topic | 2 | 2008 | 40 | 0.520 |
Why?
|
| World Health Organization | 8 | 2022 | 137 | 0.510 |
Why?
|
| Health Personnel | 3 | 2017 | 231 | 0.510 |
Why?
|
| Acyclovir | 3 | 2015 | 11 | 0.510 |
Why?
|
| Skin Tests | 8 | 2018 | 14 | 0.510 |
Why?
|
| Infectious Disease Transmission, Vertical | 8 | 2009 | 472 | 0.510 |
Why?
|
| Lymphoma | 1 | 2015 | 4 | 0.510 |
Why?
|
| Allergens | 3 | 2011 | 4 | 0.500 |
Why?
|
| Immunoglobulin G | 8 | 2022 | 231 | 0.500 |
Why?
|
| Molecular Sequence Data | 11 | 2015 | 263 | 0.490 |
Why?
|
| Didanosine | 1 | 2014 | 11 | 0.460 |
Why?
|
| Peptide Fragments | 1 | 2014 | 37 | 0.460 |
Why?
|
| Hypersensitivity | 3 | 2011 | 7 | 0.460 |
Why?
|
| Immunoassay | 5 | 2022 | 28 | 0.460 |
Why?
|
| Automation | 4 | 2012 | 8 | 0.460 |
Why?
|
| Time Factors | 11 | 2024 | 507 | 0.450 |
Why?
|
| Organophosphonates | 5 | 2015 | 45 | 0.450 |
Why?
|
| HIV Reverse Transcriptase | 7 | 2013 | 41 | 0.450 |
Why?
|
| Lymphoma, B-Cell | 2 | 2011 | 11 | 0.440 |
Why?
|
| Risk Factors | 11 | 2024 | 1475 | 0.440 |
Why?
|
| Adenine | 5 | 2015 | 91 | 0.440 |
Why?
|
| Africa South of the Sahara | 16 | 2021 | 353 | 0.430 |
Why?
|
| HIV Core Protein p24 | 5 | 2006 | 18 | 0.430 |
Why?
|
| Communicable Disease Control | 3 | 2023 | 101 | 0.420 |
Why?
|
| Scleroderma, Diffuse | 3 | 2018 | 7 | 0.420 |
Why?
|
| AIDS Vaccines | 3 | 2014 | 152 | 0.420 |
Why?
|
| Treatment Outcome | 15 | 2021 | 889 | 0.410 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 11 | 0.410 |
Why?
|
| Thymidine | 2 | 2011 | 6 | 0.410 |
Why?
|
| Logistic Models | 7 | 2023 | 254 | 0.400 |
Why?
|
| Drug Hypersensitivity | 2 | 2011 | 2 | 0.400 |
Why?
|
| DNA Primers | 4 | 2013 | 55 | 0.400 |
Why?
|
| Viremia | 2 | 2023 | 66 | 0.390 |
Why?
|
| Immunoglobulin E | 7 | 2011 | 9 | 0.390 |
Why?
|
| Monocytes | 5 | 2012 | 27 | 0.390 |
Why?
|
| Medical Laboratory Science | 2 | 2016 | 4 | 0.380 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 253 | 0.380 |
Why?
|
| Basophil Degranulation Test | 2 | 2008 | 2 | 0.380 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 25 | 0.380 |
Why?
|
| Sequence Analysis, DNA | 10 | 2016 | 181 | 0.370 |
Why?
|
| Pyridazines | 2 | 2014 | 6 | 0.370 |
Why?
|
| Plasma | 5 | 2020 | 39 | 0.360 |
Why?
|
| Betula | 2 | 2011 | 2 | 0.360 |
Why?
|
| Antigens, Plant | 2 | 2011 | 2 | 0.360 |
Why?
|
| Hemoglobins | 3 | 2016 | 40 | 0.360 |
Why?
|
| Health Care Costs | 3 | 2017 | 115 | 0.350 |
Why?
|
| Latex Hypersensitivity | 1 | 2010 | 1 | 0.350 |
Why?
|
| Latex | 1 | 2010 | 3 | 0.350 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2023 | 7 | 0.340 |
Why?
|
| Genes, Viral | 1 | 2009 | 11 | 0.340 |
Why?
|
| Retrospective Studies | 7 | 2022 | 799 | 0.340 |
Why?
|
| Pollen | 1 | 2009 | 1 | 0.340 |
Why?
|
| Malus | 1 | 2009 | 1 | 0.340 |
Why?
|
| Food Hypersensitivity | 1 | 2009 | 2 | 0.330 |
Why?
|
| Saliva | 1 | 2009 | 22 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 5 | 2024 | 253 | 0.330 |
Why?
|
| Immunoglobulin A | 5 | 2021 | 39 | 0.330 |
Why?
|
| Virology | 1 | 2009 | 13 | 0.330 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2012 | 7 | 0.320 |
Why?
|
| Zambia | 6 | 2020 | 115 | 0.320 |
Why?
|
| Africa | 12 | 2017 | 376 | 0.320 |
Why?
|
| International Cooperation | 2 | 2014 | 50 | 0.320 |
Why?
|
| Unemployment | 2 | 2020 | 10 | 0.310 |
Why?
|
| Valine | 1 | 2008 | 6 | 0.310 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 1422 | 0.310 |
Why?
|
| Volunteers | 1 | 2008 | 3 | 0.310 |
Why?
|
| Health Plan Implementation | 3 | 2017 | 16 | 0.300 |
Why?
|
| Poverty | 5 | 2020 | 152 | 0.300 |
Why?
|
| CD8 Antigens | 1 | 2008 | 3 | 0.300 |
Why?
|
| Comprehensive Health Care | 1 | 2008 | 5 | 0.300 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 48 | 0.290 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2009 | 529 | 0.290 |
Why?
|
| Lopinavir | 5 | 2015 | 137 | 0.290 |
Why?
|
| Ritonavir | 5 | 2015 | 137 | 0.290 |
Why?
|
| Desensitization, Immunologic | 1 | 2007 | 1 | 0.290 |
Why?
|
| Wasp Venoms | 1 | 2007 | 1 | 0.290 |
Why?
|
| Cytokines | 3 | 2011 | 107 | 0.280 |
Why?
|
| Early Diagnosis | 3 | 2018 | 82 | 0.280 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 5 | 2016 | 29 | 0.280 |
Why?
|
| Liver Cirrhosis | 2 | 2019 | 28 | 0.280 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2018 | 195 | 0.270 |
Why?
|
| Monitoring, Physiologic | 2 | 2018 | 25 | 0.270 |
Why?
|
| Medication Adherence | 3 | 2020 | 151 | 0.270 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2003 | 158 | 0.270 |
Why?
|
| Drug Therapy, Combination | 5 | 2021 | 279 | 0.270 |
Why?
|
| Lipid Metabolism | 3 | 2019 | 44 | 0.270 |
Why?
|
| Killer Cells, Natural | 3 | 2011 | 52 | 0.260 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 34 | 0.260 |
Why?
|
| HIV Seroprevalence | 1 | 2006 | 15 | 0.260 |
Why?
|
| Infant, Newborn | 10 | 2016 | 1479 | 0.260 |
Why?
|
| Hypertension, Pulmonary | 2 | 2023 | 8 | 0.260 |
Why?
|
| HIV Protease Inhibitors | 2 | 2016 | 92 | 0.260 |
Why?
|
| Herpes Genitalis | 4 | 2009 | 43 | 0.250 |
Why?
|
| Mining | 1 | 2006 | 41 | 0.250 |
Why?
|
| Molecular Biology | 1 | 2005 | 7 | 0.250 |
Why?
|
| Quality Control | 4 | 2014 | 27 | 0.250 |
Why?
|
| Infant Care | 1 | 2005 | 10 | 0.250 |
Why?
|
| Oligonucleotides | 1 | 2005 | 19 | 0.240 |
Why?
|
| Alanine Transaminase | 2 | 2016 | 23 | 0.240 |
Why?
|
| T-Lymphocytes | 2 | 2003 | 65 | 0.240 |
Why?
|
| Heterosexuality | 4 | 2019 | 30 | 0.240 |
Why?
|
| Creatinine | 2 | 2016 | 53 | 0.240 |
Why?
|
| Pilot Projects | 6 | 2018 | 179 | 0.240 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 188 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 127 | 0.230 |
Why?
|
| Herpesvirus 2, Human | 5 | 2015 | 43 | 0.230 |
Why?
|
| Intracellular Fluid | 1 | 2003 | 3 | 0.220 |
Why?
|
| Extracellular Fluid | 1 | 2003 | 5 | 0.220 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 370 | 0.220 |
Why?
|
| Australia | 5 | 2023 | 48 | 0.220 |
Why?
|
| Nasopharynx | 2 | 2022 | 151 | 0.220 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 1 | 0.220 |
Why?
|
| Dendritic Cells | 1 | 2003 | 4 | 0.220 |
Why?
|
| Antibodies, Antinuclear | 4 | 2017 | 13 | 0.220 |
Why?
|
| Fetal Blood | 1 | 2003 | 27 | 0.210 |
Why?
|
| Lymph Nodes | 2 | 2014 | 13 | 0.210 |
Why?
|
| Cities | 1 | 2023 | 37 | 0.210 |
Why?
|
| Health Policy | 4 | 2017 | 140 | 0.210 |
Why?
|
| Tenofovir | 5 | 2015 | 171 | 0.210 |
Why?
|
| Antigen-Antibody Complex | 4 | 1990 | 11 | 0.210 |
Why?
|
| Blood Cell Count | 3 | 2009 | 15 | 0.210 |
Why?
|
| Stavudine | 5 | 2014 | 78 | 0.210 |
Why?
|
| Deoxycytidine | 2 | 2012 | 12 | 0.200 |
Why?
|
| Skin | 2 | 2019 | 38 | 0.200 |
Why?
|
| Analysis of Variance | 3 | 2017 | 64 | 0.200 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2021 | 3 | 0.200 |
Why?
|
| Cryopreservation | 2 | 2014 | 4 | 0.190 |
Why?
|
| Lipopolysaccharides | 5 | 2011 | 37 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2022 | 31 | 0.190 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2021 | 2 | 0.190 |
Why?
|
| Seroepidemiologic Studies | 2 | 2020 | 109 | 0.190 |
Why?
|
| Pregnancy | 8 | 2012 | 1862 | 0.190 |
Why?
|
| Antigens, CD | 4 | 2010 | 26 | 0.190 |
Why?
|
| Receptors, CXCR4 | 3 | 2019 | 28 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 13 | 0.190 |
Why?
|
| Prognosis | 5 | 2022 | 199 | 0.190 |
Why?
|
| Immunoglobulin M | 6 | 2021 | 24 | 0.190 |
Why?
|
| Receptors, CCR5 | 3 | 2019 | 54 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 6 | 0.190 |
Why?
|
| Vasodilator Agents | 1 | 2021 | 11 | 0.190 |
Why?
|
| Health Resources | 3 | 2014 | 66 | 0.190 |
Why?
|
| Thromboplastin | 2 | 2012 | 9 | 0.180 |
Why?
|
| Odds Ratio | 5 | 2022 | 133 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2014 | 60 | 0.180 |
Why?
|
| Multivariate Analysis | 5 | 2022 | 171 | 0.180 |
Why?
|
| Software | 3 | 2012 | 37 | 0.180 |
Why?
|
| Home Care Services | 1 | 2021 | 15 | 0.180 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 64 | 0.180 |
Why?
|
| Research Design | 3 | 2019 | 124 | 0.180 |
Why?
|
| Contact Tracing | 1 | 2021 | 48 | 0.180 |
Why?
|
| Financing, Government | 1 | 2020 | 11 | 0.180 |
Why?
|
| Belgium | 2 | 2018 | 6 | 0.180 |
Why?
|
| Gender-Based Violence | 1 | 2020 | 12 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2020 | 12 | 0.170 |
Why?
|
| Nails | 1 | 2020 | 2 | 0.170 |
Why?
|
| Microscopic Angioscopy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Raynaud Disease | 1 | 2020 | 5 | 0.170 |
Why?
|
| Interferons | 1 | 2019 | 9 | 0.170 |
Why?
|
| Pulmonary Fibrosis | 1 | 2019 | 9 | 0.170 |
Why?
|
| Phylogeny | 6 | 2022 | 231 | 0.170 |
Why?
|
| In Vitro Techniques | 3 | 2007 | 54 | 0.170 |
Why?
|
| Quality of Life | 2 | 2023 | 177 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 239 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 8 | 0.160 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2019 | 22 | 0.160 |
Why?
|
| Dried Blood Spot Testing | 2 | 2022 | 24 | 0.160 |
Why?
|
| Medication Therapy Management | 2 | 2021 | 5 | 0.160 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2019 | 4 | 0.160 |
Why?
|
| Antigens, Viral | 2 | 2012 | 21 | 0.160 |
Why?
|
| Transportation | 1 | 2018 | 7 | 0.160 |
Why?
|
| Breath Tests | 1 | 2018 | 3 | 0.160 |
Why?
|
| Asthma | 3 | 2003 | 33 | 0.160 |
Why?
|
| Hospitalization | 1 | 2022 | 418 | 0.160 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 5 | 0.160 |
Why?
|
| Exhalation | 1 | 2018 | 3 | 0.160 |
Why?
|
| Rifabutin | 1 | 2018 | 4 | 0.160 |
Why?
|
| Tanzania | 4 | 2014 | 88 | 0.160 |
Why?
|
| Feces | 1 | 2018 | 30 | 0.160 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2018 | 20 | 0.160 |
Why?
|
| Immune Reconstitution | 1 | 2018 | 2 | 0.150 |
Why?
|
| Lamivudine | 3 | 2013 | 89 | 0.150 |
Why?
|
| Patient Transfer | 1 | 2018 | 6 | 0.150 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2018 | 9 | 0.150 |
Why?
|
| CD3 Complex | 3 | 2010 | 14 | 0.150 |
Why?
|
| Incidence | 6 | 2019 | 685 | 0.150 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 22 | 0.150 |
Why?
|
| Occupational Exposure | 2 | 2015 | 35 | 0.150 |
Why?
|
| Lung | 2 | 2023 | 70 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2017 | 4 | 0.150 |
Why?
|
| Drug Costs | 1 | 2017 | 18 | 0.150 |
Why?
|
| Biomarkers | 6 | 2023 | 327 | 0.150 |
Why?
|
| Interferon-gamma Release Tests | 2 | 2015 | 8 | 0.140 |
Why?
|
| Mycophenolic Acid | 1 | 2017 | 1 | 0.140 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 5 | 0.140 |
Why?
|
| Methotrexate | 1 | 2017 | 17 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2017 | 20 | 0.140 |
Why?
|
| Tuberculin Test | 2 | 2015 | 49 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 20 | 0.140 |
Why?
|
| Aging | 2 | 2011 | 109 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 125 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2017 | 62 | 0.140 |
Why?
|
| DNA-Directed RNA Polymerases | 2 | 2018 | 5 | 0.140 |
Why?
|
| Fingers | 1 | 2016 | 1 | 0.130 |
Why?
|
| Skin Ulcer | 1 | 2016 | 3 | 0.130 |
Why?
|
| Calcinosis | 1 | 2016 | 11 | 0.130 |
Why?
|
| Osteoporosis | 1 | 2016 | 14 | 0.130 |
Why?
|
| Base Sequence | 2 | 2014 | 149 | 0.130 |
Why?
|
| Operations Research | 1 | 2016 | 3 | 0.130 |
Why?
|
| Inventions | 1 | 2016 | 1 | 0.130 |
Why?
|
| Genome, Viral | 2 | 2022 | 64 | 0.130 |
Why?
|
| Databases as Topic | 1 | 2015 | 6 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2015 | 10 | 0.130 |
Why?
|
| Lactic Acid | 1 | 2016 | 34 | 0.130 |
Why?
|
| Cells, Cultured | 5 | 2009 | 79 | 0.130 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2016 | 11 | 0.130 |
Why?
|
| Africa, Southern | 3 | 2010 | 91 | 0.130 |
Why?
|
| Ribonucleoproteins | 1 | 2015 | 6 | 0.130 |
Why?
|
| Markov Chains | 2 | 2012 | 22 | 0.130 |
Why?
|
| Herpes Zoster | 1 | 2015 | 4 | 0.130 |
Why?
|
| Nucleic Acids | 1 | 2015 | 7 | 0.120 |
Why?
|
| Dinitrobenzenes | 1 | 1995 | 1 | 0.120 |
Why?
|
| Methemoglobin | 1 | 1995 | 1 | 0.120 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 303 | 0.120 |
Why?
|
| Bacterial Proteins | 2 | 2018 | 119 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 237 | 0.120 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 11 | 0.120 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 1997 | 35 | 0.120 |
Why?
|
| Chemoprevention | 1 | 2015 | 33 | 0.120 |
Why?
|
| Occupational Health | 1 | 2015 | 24 | 0.120 |
Why?
|
| Mycobacterium | 1 | 2015 | 16 | 0.120 |
Why?
|
| Hepatitis B virus | 2 | 2013 | 157 | 0.120 |
Why?
|
| Monitoring, Immunologic | 1 | 2014 | 1 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 198 | 0.120 |
Why?
|
| Thrombosis | 2 | 2009 | 47 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 38 | 0.120 |
Why?
|
| Body Fluids | 1 | 2014 | 5 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 34 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 280 | 0.110 |
Why?
|
| Dideoxynucleosides | 1 | 2014 | 29 | 0.110 |
Why?
|
| Transcriptome | 1 | 2014 | 14 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 7 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1994 | 7 | 0.110 |
Why?
|
| Nitriles | 2 | 2014 | 27 | 0.110 |
Why?
|
| Lipopolysaccharide Receptors | 4 | 2012 | 10 | 0.110 |
Why?
|
| Viral Tropism | 1 | 2013 | 9 | 0.110 |
Why?
|
| Rheumatoid Factor | 3 | 2007 | 16 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 262 | 0.110 |
Why?
|
| Zidovudine | 3 | 2013 | 59 | 0.110 |
Why?
|
| Pyrimidines | 2 | 2014 | 32 | 0.110 |
Why?
|
| India | 3 | 2024 | 62 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 1994 | 29 | 0.110 |
Why?
|
| Rhinitis | 2 | 1984 | 5 | 0.110 |
Why?
|
| Diagnostic Errors | 2 | 2011 | 18 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 51 | 0.110 |
Why?
|
| Antibodies | 3 | 2010 | 25 | 0.110 |
Why?
|
| RNA Polymerase III | 3 | 2018 | 5 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 59 | 0.110 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 45 | 0.110 |
Why?
|
| Reference Values | 3 | 2009 | 64 | 0.110 |
Why?
|
| Cryptococcus | 1 | 2012 | 10 | 0.100 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2012 | 16 | 0.100 |
Why?
|
| Autoantigens | 1 | 2012 | 10 | 0.100 |
Why?
|
| Diagnostic Equipment | 1 | 2012 | 3 | 0.100 |
Why?
|
| Human Immunodeficiency Virus Proteins | 2 | 2009 | 10 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 42 | 0.100 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2010 | 104 | 0.100 |
Why?
|
| Cerebrospinal Fluid | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 4 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2012 | 19 | 0.100 |
Why?
|
| Public Health Administration | 1 | 2012 | 14 | 0.100 |
Why?
|
| P-Selectin | 1 | 2012 | 7 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2003 | 44 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 57 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2012 | 7 | 0.100 |
Why?
|
| Immunoglobulins | 2 | 2021 | 11 | 0.100 |
Why?
|
| Platelet Activation | 1 | 2012 | 17 | 0.100 |
Why?
|
| HIV Protease | 1 | 2012 | 22 | 0.100 |
Why?
|
| Europe | 3 | 2017 | 56 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2013 | 125 | 0.100 |
Why?
|
| Physical Examination | 1 | 2011 | 10 | 0.100 |
Why?
|
| Blood Platelets | 1 | 2012 | 30 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2021 | 149 | 0.100 |
Why?
|
| Liver | 1 | 2012 | 74 | 0.100 |
Why?
|
| Bacterial Translocation | 1 | 2011 | 2 | 0.100 |
Why?
|
| Capacity Building | 1 | 2012 | 32 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 61 | 0.100 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2011 | 33 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2012 | 49 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2011 | 33 | 0.090 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 53 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 23 | 0.090 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 101 | 0.090 |
Why?
|
| ROC Curve | 3 | 2018 | 51 | 0.090 |
Why?
|
| Androstanols | 1 | 2011 | 1 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 37 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2011 | 11 | 0.090 |
Why?
|
| Nut Hypersensitivity | 1 | 2011 | 1 | 0.090 |
Why?
|
| Corylus | 1 | 2011 | 1 | 0.090 |
Why?
|
| Plant Proteins | 1 | 2011 | 4 | 0.090 |
Why?
|
| Sexual Behavior | 3 | 2012 | 320 | 0.090 |
Why?
|
| Bacteremia | 1 | 2011 | 79 | 0.090 |
Why?
|
| United States | 3 | 2016 | 132 | 0.090 |
Why?
|
| Sequence Deletion | 1 | 2010 | 16 | 0.090 |
Why?
|
| Sjogren's Syndrome | 1 | 1990 | 2 | 0.090 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2010 | 3 | 0.090 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 3 | 0.090 |
Why?
|
| Asia | 3 | 2017 | 72 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 4 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 5 | 0.090 |
Why?
|
| Leptin | 1 | 2010 | 26 | 0.090 |
Why?
|
| Disulfides | 1 | 2010 | 6 | 0.090 |
Why?
|
| HIV Integrase | 1 | 2010 | 6 | 0.090 |
Why?
|
| Adiposity | 1 | 2011 | 96 | 0.090 |
Why?
|
| Information Storage and Retrieval | 2 | 2022 | 13 | 0.090 |
Why?
|
| Viral Proteins | 1 | 2010 | 30 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 73 | 0.090 |
Why?
|
| Antibody Formation | 2 | 1989 | 61 | 0.090 |
Why?
|
| Drug Administration Schedule | 4 | 2012 | 156 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 435 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2015 | 272 | 0.080 |
Why?
|
| HIV Long-Term Survivors | 1 | 2009 | 8 | 0.080 |
Why?
|
| Nevirapine | 2 | 2013 | 146 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 125 | 0.080 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2009 | 4 | 0.080 |
Why?
|
| Government Programs | 1 | 2009 | 30 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1989 | 5 | 0.080 |
Why?
|
| Syndrome | 1 | 2009 | 19 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 40 | 0.080 |
Why?
|
| Placenta | 1 | 1989 | 44 | 0.080 |
Why?
|
| Blood Donors | 1 | 2009 | 19 | 0.080 |
Why?
|
| Prenatal Diagnosis | 1 | 2009 | 22 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2009 | 127 | 0.080 |
Why?
|
| National Health Programs | 2 | 2022 | 78 | 0.080 |
Why?
|
| Rural Health | 1 | 2009 | 118 | 0.080 |
Why?
|
| Genitalia, Female | 1 | 2008 | 17 | 0.080 |
Why?
|
| Interleukin-3 | 1 | 2008 | 1 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 2 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2008 | 6 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 293 | 0.070 |
Why?
|
| Fluorescence | 1 | 2008 | 9 | 0.070 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 52 | 0.070 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2006 | 18 | 0.070 |
Why?
|
| Genes, vpr | 1 | 2007 | 2 | 0.070 |
Why?
|
| Genes, vpu | 1 | 2007 | 2 | 0.070 |
Why?
|
| Genes, vif | 1 | 2007 | 2 | 0.070 |
Why?
|
| Clinical Protocols | 2 | 2017 | 26 | 0.070 |
Why?
|
| Peptides, Cyclic | 1 | 2007 | 8 | 0.070 |
Why?
|
| Phlebotomy | 1 | 2006 | 6 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 21 | 0.070 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2017 | 4 | 0.070 |
Why?
|
| Vaccines, DNA | 1 | 2006 | 11 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 8 | 0.070 |
Why?
|
| Support Vector Machine | 2 | 2018 | 5 | 0.070 |
Why?
|
| Dermatitis, Atopic | 2 | 2003 | 3 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2009 | 51 | 0.070 |
Why?
|
| Cough | 2 | 1984 | 14 | 0.070 |
Why?
|
| Autoantibodies | 2 | 2017 | 49 | 0.070 |
Why?
|
| Animals | 2 | 2022 | 1081 | 0.060 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2005 | 4 | 0.060 |
Why?
|
| Neonatal Screening | 1 | 2006 | 24 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2005 | 2 | 0.060 |
Why?
|
| Oligonucleotide Probes | 1 | 2005 | 6 | 0.060 |
Why?
|
| Comorbidity | 2 | 2016 | 188 | 0.060 |
Why?
|
| Survival Rate | 2 | 2017 | 96 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2010 | 139 | 0.060 |
Why?
|
| Age Factors | 4 | 2016 | 370 | 0.060 |
Why?
|
| Moldova | 1 | 2024 | 3 | 0.060 |
Why?
|
| HLA-DR Antigens | 3 | 2012 | 13 | 0.060 |
Why?
|
| Endpoint Determination | 2 | 2015 | 8 | 0.060 |
Why?
|
| Acute Disease | 1 | 2004 | 105 | 0.060 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 44 | 0.060 |
Why?
|
| Cost Savings | 1 | 2004 | 7 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 13 | 0.060 |
Why?
|
| Eosinophilia | 1 | 1984 | 2 | 0.060 |
Why?
|
| Disease Outbreaks | 2 | 2018 | 111 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2003 | 7 | 0.060 |
Why?
|
| Microspheres | 1 | 2003 | 8 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2003 | 142 | 0.050 |
Why?
|
| Thailand | 2 | 2014 | 26 | 0.050 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2023 | 1 | 0.050 |
Why?
|
| Cell Separation | 1 | 2003 | 6 | 0.050 |
Why?
|
| Sexual Partners | 3 | 2010 | 215 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2023 | 20 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2003 | 4 | 0.050 |
Why?
|
| Mothers | 1 | 2005 | 195 | 0.050 |
Why?
|
| Benchmarking | 1 | 2003 | 10 | 0.050 |
Why?
|
| United Kingdom | 1 | 2003 | 33 | 0.050 |
Why?
|
| Respiratory Hypersensitivity | 1 | 1983 | 1 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2003 | 29 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 26 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 16 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2014 | 89 | 0.050 |
Why?
|
| Alkynes | 2 | 2013 | 117 | 0.050 |
Why?
|
| Cyclopropanes | 2 | 2013 | 123 | 0.050 |
Why?
|
| Binding Sites | 2 | 2008 | 43 | 0.050 |
Why?
|
| Emtricitabine | 2 | 2012 | 78 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 411 | 0.050 |
Why?
|
| Interleukin-2 | 2 | 1993 | 22 | 0.050 |
Why?
|
| Botswana | 1 | 2022 | 24 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2022 | 27 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 4 | 0.050 |
Why?
|
| Benzoxazines | 2 | 2013 | 123 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 15 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2022 | 84 | 0.050 |
Why?
|
| Uganda | 2 | 2013 | 197 | 0.050 |
Why?
|
| Vincristine | 1 | 2021 | 5 | 0.050 |
Why?
|
| Malaria | 2 | 2003 | 213 | 0.050 |
Why?
|
| Rituximab | 1 | 2021 | 4 | 0.050 |
Why?
|
| Monensin | 1 | 2001 | 1 | 0.050 |
Why?
|
| Brefeldin A | 1 | 2001 | 1 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2001 | 12 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 33 | 0.050 |
Why?
|
| Leukocyte Count | 4 | 2003 | 24 | 0.050 |
Why?
|
| Foster Home Care | 1 | 2000 | 3 | 0.050 |
Why?
|
| Africa, Eastern | 2 | 2010 | 17 | 0.050 |
Why?
|
| Child Health Services | 1 | 2020 | 35 | 0.040 |
Why?
|
| Maternal Health Services | 1 | 2020 | 52 | 0.040 |
Why?
|
| Cell Line | 2 | 2010 | 93 | 0.040 |
Why?
|
| Taxes | 1 | 2020 | 73 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Semen | 1 | 2019 | 3 | 0.040 |
Why?
|
| Genitalia | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cell Survival | 2 | 2014 | 48 | 0.040 |
Why?
|
| Mortality, Premature | 1 | 2019 | 6 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 124 | 0.040 |
Why?
|
| Cervix Uteri | 2 | 2009 | 22 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2018 | 1 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Community Networks | 1 | 2018 | 13 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2006 | 39 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 20 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 321 | 0.040 |
Why?
|
| Machine Learning | 1 | 2018 | 22 | 0.040 |
Why?
|
| Urban Population | 1 | 2021 | 257 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 176 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2018 | 80 | 0.040 |
Why?
|
| Vagina | 2 | 2009 | 91 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 20 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 99 | 0.040 |
Why?
|
| Victoria | 1 | 2017 | 2 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 63 | 0.040 |
Why?
|
| Brazil | 1 | 2017 | 47 | 0.040 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 1997 | 1 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1997 | 5 | 0.040 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 1997 | 4 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1997 | 9 | 0.040 |
Why?
|
| Glycoproteins | 1 | 1997 | 10 | 0.040 |
Why?
|
| Prothrombin | 1 | 1997 | 8 | 0.040 |
Why?
|
| Risk | 1 | 2017 | 87 | 0.040 |
Why?
|
| Sequence Alignment | 2 | 2008 | 59 | 0.040 |
Why?
|
| Ethionamide | 1 | 2017 | 9 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 154 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2017 | 54 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 2017 | 8 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1994 | 5 | 0.040 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 7 | 0.040 |
Why?
|
| Medical Audit | 1 | 2017 | 26 | 0.030 |
Why?
|
| Gene Products, pol | 1 | 2016 | 5 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2012 | 11 | 0.030 |
Why?
|
| Job Description | 1 | 2016 | 1 | 0.030 |
Why?
|
| Work Capacity Evaluation | 1 | 2016 | 2 | 0.030 |
Why?
|
| Amputation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Telangiectasis | 1 | 2016 | 1 | 0.030 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2016 | 1 | 0.030 |
Why?
|
| Acro-Osteolysis | 1 | 2016 | 1 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 45 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2016 | 19 | 0.030 |
Why?
|
| Interleukin-7 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 22 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2015 | 10 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2015 | 15 | 0.030 |
Why?
|
| Sex Factors | 2 | 2009 | 227 | 0.030 |
Why?
|
| Canada | 1 | 2015 | 11 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2015 | 30 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2015 | 81 | 0.030 |
Why?
|
| Carboxyhemoglobin | 1 | 1995 | 1 | 0.030 |
Why?
|
| Chemical Fractionation | 1 | 1995 | 1 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 1995 | 2 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1995 | 3 | 0.030 |
Why?
|
| Global Health | 1 | 2016 | 193 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1995 | 8 | 0.030 |
Why?
|
| Placebos | 1 | 2015 | 44 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1995 | 18 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 106 | 0.030 |
Why?
|
| Cattle | 1 | 1995 | 28 | 0.030 |
Why?
|
| Workload | 1 | 2015 | 13 | 0.030 |
Why?
|
| MEDLINE | 1 | 2015 | 2 | 0.030 |
Why?
|
| Infection Control | 1 | 2015 | 31 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2015 | 4 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 163 | 0.030 |
Why?
|
| Species Specificity | 1 | 2015 | 49 | 0.030 |
Why?
|
| Mortality | 1 | 2015 | 104 | 0.030 |
Why?
|
| Workflow | 1 | 2014 | 4 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 17 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2014 | 7 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 32 | 0.030 |
Why?
|
| Consensus | 1 | 2014 | 62 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 4 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 1994 | 18 | 0.030 |
Why?
|
| Malawi | 1 | 2014 | 87 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 41 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 43 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 2013 | 12 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2013 | 48 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2013 | 26 | 0.030 |
Why?
|
| Temperature | 1 | 2013 | 56 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2013 | 64 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 42 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2012 | 17 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2012 | 16 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2012 | 31 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2012 | 42 | 0.030 |
Why?
|
| Inflammation | 1 | 1993 | 104 | 0.030 |
Why?
|
| Patient Selection | 1 | 2012 | 40 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 17 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2012 | 23 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 1992 | 10 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 42 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1992 | 34 | 0.020 |
Why?
|
| Contraception Behavior | 1 | 2012 | 54 | 0.020 |
Why?
|
| Lost to Follow-Up | 1 | 2012 | 62 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2012 | 115 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 9 | 0.020 |
Why?
|
| Depression | 1 | 1993 | 121 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 37 | 0.020 |
Why?
|
| Nigeria | 1 | 2011 | 49 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 85 | 0.020 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2011 | 1 | 0.020 |
Why?
|
| Vecuronium Bromide | 1 | 2011 | 1 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 8 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 111 | 0.020 |
Why?
|
| Zimbabwe | 1 | 2011 | 120 | 0.020 |
Why?
|
| Codon | 1 | 2010 | 7 | 0.020 |
Why?
|
| Pacific Islands | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2011 | 44 | 0.020 |
Why?
|
| Kenya | 1 | 2011 | 183 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2010 | 47 | 0.020 |
Why?
|
| CD57 Antigens | 1 | 1990 | 1 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1990 | 2 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1990 | 3 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1990 | 10 | 0.020 |
Why?
|
| Geography | 1 | 2010 | 60 | 0.020 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2010 | 3 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2010 | 5 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 16 | 0.020 |
Why?
|
| Glucose | 1 | 2010 | 45 | 0.020 |
Why?
|
| Protein Folding | 1 | 2010 | 4 | 0.020 |
Why?
|
| Training Support | 1 | 2010 | 4 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2010 | 45 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 62 | 0.020 |
Why?
|
| Pyrrolidinones | 1 | 2010 | 6 | 0.020 |
Why?
|
| Quinolones | 1 | 2010 | 7 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 1990 | 28 | 0.020 |
Why?
|
| Physicians | 1 | 2010 | 31 | 0.020 |
Why?
|
| Raltegravir Potassium | 1 | 2010 | 14 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 77 | 0.020 |
Why?
|
| Blood Physiological Phenomena | 1 | 1989 | 3 | 0.020 |
Why?
|
| Fluoresceins | 1 | 1989 | 2 | 0.020 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2010 | 33 | 0.020 |
Why?
|
| Flagellin | 1 | 2009 | 3 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 1989 | 22 | 0.020 |
Why?
|
| Complement C3 | 1 | 1989 | 1 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2009 | 19 | 0.020 |
Why?
|
| Virus Shedding | 1 | 2009 | 24 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 2008 | 4 | 0.020 |
Why?
|
| Virus Replication | 1 | 2009 | 88 | 0.020 |
Why?
|
| Menstrual Hygiene Products | 1 | 2008 | 8 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2010 | 175 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2010 | 480 | 0.020 |
Why?
|
| Humidity | 1 | 2008 | 5 | 0.020 |
Why?
|
| Giant Cells | 1 | 2008 | 3 | 0.020 |
Why?
|
| Glycosylation | 1 | 2008 | 17 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 28 | 0.020 |
Why?
|
| Genes, env | 1 | 2008 | 9 | 0.020 |
Why?
|
| Pepsin A | 1 | 1988 | 1 | 0.020 |
Why?
|
| Outliers, DRG | 1 | 2008 | 1 | 0.020 |
Why?
|
| Sarcoma, Kaposi | 2 | 1985 | 53 | 0.020 |
Why?
|
| Feedback | 1 | 2008 | 6 | 0.020 |
Why?
|
| Health Surveys | 1 | 2008 | 59 | 0.020 |
Why?
|
| Phenotype | 1 | 2008 | 158 | 0.020 |
Why?
|
| Gene Products, vpr | 1 | 2007 | 2 | 0.020 |
Why?
|
| Gene Products, vif | 1 | 2007 | 2 | 0.020 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2007 | 2 | 0.020 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2007 | 2 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2007 | 10 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2006 | 1 | 0.020 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2007 | 27 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2006 | 12 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 22 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 31 | 0.020 |
Why?
|
| Developed Countries | 1 | 2006 | 24 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2006 | 72 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 14 | 0.020 |
Why?
|
| Deltaretrovirus | 1 | 1985 | 1 | 0.020 |
Why?
|
| Chlamydia trachomatis | 1 | 2005 | 13 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2005 | 4 | 0.020 |
Why?
|
| Chlamydia Infections | 1 | 2005 | 17 | 0.020 |
Why?
|
| Gonorrhea | 1 | 2005 | 20 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1985 | 1 | 0.020 |
Why?
|
| Perinatal Care | 1 | 2005 | 21 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 89 | 0.020 |
Why?
|
| Health Education | 1 | 2005 | 35 | 0.020 |
Why?
|
| Plasmodium falciparum | 1 | 1985 | 64 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2005 | 60 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2005 | 121 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2005 | 120 | 0.010 |
Why?
|
| Vaccination | 1 | 2006 | 365 | 0.010 |
Why?
|
| Eczema | 1 | 1984 | 4 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2003 | 7 | 0.010 |
Why?
|
| Immunoglobulin D | 1 | 1983 | 4 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 34 | 0.010 |
Why?
|
| Gastric Juice | 1 | 2002 | 6 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2002 | 29 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 1993 | 27 | 0.010 |
Why?
|
| Smoking | 1 | 1983 | 100 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2001 | 1 | 0.010 |
Why?
|
| Ionophores | 1 | 2001 | 3 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1997 | 5 | 0.010 |
Why?
|
| beta 2-Glycoprotein I | 1 | 1997 | 4 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 1997 | 96 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1993 | 6 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1993 | 133 | 0.010 |
Why?
|
| Democratic Republic of the Congo | 1 | 1985 | 10 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1985 | 20 | 0.000 |
Why?
|